Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. | Eli Lilly has filed lawsuits against six U.S. companies, accusing them of selling illegal versions of its ...

More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's interim CEO, Alan Bash ...

With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the potential to hit pr | ...

In a deal announced this week, Alfasigma spent an undisclosed sum to continue its global expansion in immunology.  | Alfasigma will add key drugs like Nordimet through the deal, as well as Nordic ...

Fresenius Kabi is yanking a batch of another product in the U.S., shortly after initiating a separate recall tied to mislabeled pain medicine. | Shortly after initiating a separate recall tied to ...

As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival transthyretin amyloidosis (ATTR) drug Attruby came in above analysts’ expectations. | Despite their divergent second-quarter ...

Snapchat is courting pharma marketers with a new ad format designed to support the disclosure needs of brand | Snapchat is courting pharma marketers with a new ad format designed to support the ...

WuXi AppTec has been caught in the crosshairs of ongoing scrutiny over China’s booming biotechnology industry since 2024, when the Biosecure Act, which aims to keep taxpayer dollars away from “foreign ...

Bristol Myers Squibb has laid out plans for a $2.3 billion manufacturing facility in Houston, set for completion in 2030. The plant will cover 600,000 square feet and employ nearly 500 people.

Abbott has enlisted telenovela star Gabriela Spanic to push the message that getting screened for colon cancer doesn’t have ...

Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to ...

ITM’s application rested on data from the phase 3 Compete trial in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These malignancies arise in a specialized group of neurons ...